Jérôme Moreaux, PhD is an expert in Hematology at University Hospital of Montpellier (France). As of October 2026, ScienceLeadR ranks Jérôme Moreaux in the top 1% of experts worldwide for Lymphoproliferative Disorders. Jérôme Moreaux has authored 252 publications, the most recent in 2026, and is an investigator in 2 clinical trials. SLR score: 1,128 (community average: 125). How the SLR is computed.

LeadR Profile

Jérôme Moreaux, PhD University Hospital of Montpellier France
1 128 ScienceLeadR Reputation 1128
Network Map

Hematology

Subspecialties: Immunology - Oncology - Genetics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2003 - 2026

Source: PubMed

University Hospital of Montpellier

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 252

Citations

Citations: 6 597 1st author: 26 Last author: 73 Unique author: 11


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Inflammatory bone marrow microenvironment impairs the therapeutic effect of daratumumab-lenalidomide in multiple myeloma.
PMID 42701201 — cells, genes, bone marrow, multiple myeloma, lenalidomide, therapeutics
Biomark Res20260
CD200 is a potent new growth factor in Multiple Myeloma dependent on IGF1 receptor signaling.
PMID 42664786 — cells, growth, neoplasms, multiple myeloma, therapeutics
Transl Oncol20260
A non-catalytic function for RAD18 in sustaining glioblastoma proliferation.
PMID 42397741 — cells, growth, biological science disciplines, neoplasms, chromatin, carcinogenesis, glioblastoma, ubiquitin-protein ligases
Cell Rep20260
Single-nuclei UPR profiling by flow cytometry reveals bortezomib resistance mechanisms in multiple myeloma.
PMID 42373888 — cells, flow cytometry, genes, neoplasms, bortezomib, multiple myeloma, unfolded protein response
EMBO Mol Med20260
Inhibition of SUV39H1 as a potent therapeutic target in multiple myeloma.
PMID 41988779 — multiple myeloma, therapeutics
Haematologica20260

Clinical Studies 2

Sources: ClinicalTrials, EU CTIS

Synthesis

Study Director: 1

By phase:

N/A 1
Phase 2 1

By status:

Completed 1
Unknown 1

By type:

Interventional 1
Observational 1

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 1
multicentric5to9 0
multicentricup10 0

Main Topics

LeadR Networks

Main global connection map